Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML
Publication
, Conference
Skuli, S; Vadakekolathu, J; Fenu, E; Bennett, K; Palma, J; Harris, J; Leung, O; Balar, E; Pozdnyakova, O; Bagg, A; Matthews, A; Carroll, M ...
Published in: Blood
November 3, 2025
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 3, 2025
Volume
146
Issue
Supplement 1
Start / End Page
1734 / 1734
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Skuli, S., Vadakekolathu, J., Fenu, E., Bennett, K., Palma, J., Harris, J., … Rutella, S. (2025). Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML. In Blood (Vol. 146, pp. 1734–1734). American Society of Hematology. https://doi.org/10.1182/blood-2025-1734
Skuli, Sarah, Jayakumar Vadakekolathu, Elena Fenu, Kate Bennett, Jem Palma, Jaryse Harris, Olivia Leung, et al. “Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML.” In Blood, 146:1734–1734. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-1734.
Skuli S, Vadakekolathu J, Fenu E, Bennett K, Palma J, Harris J, et al. Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML. In: Blood. American Society of Hematology; 2025. p. 1734–1734.
Skuli, Sarah, et al. “Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 1734–1734. Crossref, doi:10.1182/blood-2025-1734.
Skuli S, Vadakekolathu J, Fenu E, Bennett K, Palma J, Harris J, Leung O, Balar E, Pozdnyakova O, Bagg A, Matthews A, Carroll M, Lai C, Rutella S. Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML. Blood. American Society of Hematology; 2025. p. 1734–1734.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 3, 2025
Volume
146
Issue
Supplement 1
Start / End Page
1734 / 1734
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology